Innovative Oncology Focus ZielBio is at the forefront of cancer therapeutics research, developing groundbreaking treatments that aim to radically improve patient outcomes, making it a key player in the expanding oncology market.
Recent Leadership Changes The appointment of a new CEO, Alan Bash, in January 2023 indicates strategic leadership shifts that may drive partnership opportunities and accelerate product development timelines.
Strong Investment Backing With a significant Series A funding of $25 million led by Morningside Ventures, ZielBio demonstrates investor confidence, positioning it for rapid growth and potential cooperation in biotechnology innovations.
Collaborative Potential Being a clinical-stage company with an innovative platform, ZielBio is likely seeking collaborations for research, development, and clinical trials, creating opportunities for biotech and pharma partners.
Growth and Expansion Opportunities As a smaller firm with a focus on cutting-edge therapies and recent leadership additions, ZielBio presents opportunities for tailored solutions in research technology, lab automation, and data analytics to support its R&D pipeline.
ZielBio, Inc. uses 8 technology products and services including Open Graph, RSS, Google Cloud, and more. Explore ZielBio, Inc.'s tech stack below.
| ZielBio, Inc. Email Formats | Percentage |
| FLast@zielbio.com | 100% |
Biotechnology ResearchVirginia, United States11-50 Employees
ZielBio is a clinical-stage biotechnology company using groundbreaking technology to identify druggable and specific targets that have the potential to radically change how we treat disease. We are currently advancing several therapeutics to expand treatment options and meaningfully improve the live of patients with cancer.
Company Overview
Media & News
Funding & FinancialsZielBio, Inc.'s revenue is estimated to be in the range of $1M
Funding & FinancialsZielBio, Inc.'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com